Medtronic Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Medtronic (MDT) is set to report quarterly EPS of $1.39 (vs. $1.26 prior year) and revenue of $9.54B (vs. $8.54B last year) before the open Tuesday, Sept. 1. The stock recently fell 2.2% to $89.97, but multiple analysts maintain Buy/Outperform views, including a Needham price-target increase to $114 and a UBS upgrade to Buy to $100. The company also declared a Q2 cash dividend of $0.72 per ordinary share on Aug. 20.

Analysis

MDT is priced like a stable compounder, not a re-accelerator. With the stock around $90 and analyst targets clustering near the low-$100s, the market is effectively paying for execution but not for a step-up in organic growth; that makes the setup asymmetric around guidance, not EPS. The dividend helps defend downside for income buyers, but it does little to change the multiple unless management shows durable mix shift and margin leverage.

The second-order read-through is more important for the broader medtech basket than for MDT alone. A clean print would reduce fear that elective/procedural demand is weakening and could lift sentiment across BSX, ABT, SYK, and the IHI complex; a miss would likely rotate capital toward the higher-growth franchises with clearer secular tailwinds and away from diversified laggards. The market is likely underestimating how quickly a modest guide cut can compress the multiple by 1-2 turns, even if the headline EPS beat is intact.

Contrarian view: consensus may be over-fixated on near-term EPS and missing that the real catalyst is revenue slope into the next two quarters. If management only confirms the current run-rate, the stock can still disappoint because the dividend floor is already embedded. The main falsifier is a raised FY organic growth or margin guide; without that, a post-earnings pop should be faded rather than chased.

Key Decisions for Investors

• Do not pre-position aggressively ahead of the print; MDT’s risk/reward is guidance-driven, so the cleaner entry is after management commentary, not before.
• Buy MDT on a 4-6% post-earnings selloff only if FY organic growth and margin guidance are maintained; use a 3-6 month target back to the low-$100s, with thesis invalidated by any guide cut.
• If MDT rallies more than ~3% on a meet-and-maintain report, consider fading the move via a short-duration call spread sale or trimming exposure; the multiple likely needs a real guide raise to sustain upside.
• Relative-value watch: long SYK or BSX versus short MDT if the print shows only incremental improvement, since higher-growth device names deserve the premium when procedures are steady but not accelerating.